Despite the low histological grade and radical surgical treatment of the tumor at primary manifestation, the disease had aggressive clinical course and the response to BRAF/MEK targeted therapy administered at recurrence was complete but nondurable. The gene discussed is BRAF; the disease is neoplasm.